22 related articles for article (PubMed ID: 2188928)
1. Mitoxantrone and Mitoxantrone-Loaded Iron Oxide Nanoparticles Induce Cell Death in Human Pancreatic Ductal Adenocarcinoma Cell Spheroids.
Dinter J; Friedrich RP; Yang H; Pilarsky C; Mangge H; Pöttler M; Janko C; Alexiou C; Lyer S
Materials (Basel); 2023 Apr; 16(7):. PubMed ID: 37049199
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy for metastatic pancreatic adenocarcinoma.
Lawrence B; Findlay M
Ther Adv Med Oncol; 2010 Mar; 2(2):85-106. PubMed ID: 21789129
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
Faulds D; Balfour JA; Chrisp P; Langtry HD
Drugs; 1991 Mar; 41(3):400-49. PubMed ID: 1711446
[TBL] [Abstract][Full Text] [Related]
4. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone in the treatment of advanced non-squamous carcinoma of the cervix (a phase II trial of the gynecologic oncology group).
Muss HB; Bundy BN; Homesley HD; Wilbanks G
Invest New Drugs; 1987; 5(2):199-202. PubMed ID: 3654152
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of mitoxantrone in advanced gastric cancer.
Goldenberg A; Kelsen D; Benedetto P
Oncology; 1988; 45(4):273-5. PubMed ID: 3290754
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer.
Henderson IC; Allegra JC; Woodcock T; Wolff S; Bryan S; Cartwright K; Dukart G; Henry D
J Clin Oncol; 1989 May; 7(5):560-71. PubMed ID: 2468745
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone use in breast cancer patients with elevated bilirubin.
Chlebowski RT; Bulcavage L; Henderson IC; Woodcock T; Rivest R; Elashoff R
Breast Cancer Res Treat; 1989 Dec; 14(3):267-74. PubMed ID: 2692728
[TBL] [Abstract][Full Text] [Related]
10. Phase I clinical investigation of 1,4-dihydroxy-5,8-bis (( (2-[(2-hydroxyethyl)amino]ethyl) amino))-9,10-anthracenedione dihydrochloride (NSC 301739), a new anthracenedione.
Von Hoff DD; Pollard E; Kuhn J; Murray E; Coltman CA
Cancer Res; 1980 May; 40(5):1516-8. PubMed ID: 7370989
[TBL] [Abstract][Full Text] [Related]
11. Antineoplastic agents. Structure-activity relationship study of bis(substituted aminoalkylamino)anthraquinones.
Zee-Cheng RK; Cheng CC
J Med Chem; 1978 Mar; 21(3):291-4. PubMed ID: 628005
[TBL] [Abstract][Full Text] [Related]
12. Experimental antitumor activity of aminoanthraquinones.
Johnson RK; Zee-Cheng RK; Lee WW; Acton EM; Henry DW; Cheng CC
Cancer Treat Rep; 1979 Mar; 63(3):425-39. PubMed ID: 427824
[TBL] [Abstract][Full Text] [Related]
13. Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: a Southwest Oncology Group study.
Taylor SA; Fleming T; Von Hoff DD; McCracken JD; Bukowski RM; Talley RW; Natale RB; Guy JT; Samlowski WE; Costanzi JH
Invest New Drugs; 1990 Feb; 8(1):77-80. PubMed ID: 2188928
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
